The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

Both biotech stocks could be the breakout growth story in 2026. The post These 2 ASX healthcare shares could jump well over ...

Seasoned Life Sciences Executive Joins to Lead Operations and Scale Lahjavida’s Dye-Drug Conjugate Platform COLORADO ...

Stock Market Today: The Nasdaq ends a losing streak, but barely. Small caps close flat after a choppy action.

Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces it ...

The research, published in the journal Science Advances, details a structurally novel vaccine design where an HPV antigen and a powerful immune-stimulating adjuvant are co-engineered onto a single SNA ...

"It's not a matter of solvability," David Walsey says of his organization's battle against Lyme disease. "It's a matter of ...

AlphaTON Capital Corp. (Nasdaq: ATON) ("AlphaTON" or the "Company"), the world's leading public technology company scaling the Telegram super app for an addressable market of over 1 billion monthly ...

The one‑day event, organised by ASPIRE‑BioNEST in association with the Technology Enabling Centre, drew 45 teams comprising nearly 130 students from undergraduate, postgraduate and doctoral levels ...

The company expects to expand global distributor agreements to cover over 40 countries in 2026 and to finalize VYJUVEK pricing and launch in Italy in the second half of 2026. Management reaffirmed ...

Consider Dimerix ( ASX: DXB) which signed deals totalling $1.4bn for future sales of its kidney disease drug across 2025. Or ...

This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.